相关临床试验
0
0 进行中
药物批准
8
批准总数
监管机构
2
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Nearly a quarter of the UK's fastest-growing tech companies operate in life sciences, collectively generating £3.7 billion in revenues with £3 billion growth over three years. - Leading companies include AI-powered clinical trial platform Lindus Health with 265% revenue growth and CNS drug developer Autifony Therapeutics achieving 200% growth. - The 23 life sciences companies span diverse sectors from digital health and medical imaging to cell therapy and rare disease treatments, creating 11,600 new jobs across the industry.
- Cycle Group Holdings Limited announced a definitive agreement to acquire Applied Therapeutics for $0.088 per share plus contingent value rights worth up to $0.40 per share. - The acquisition focuses on advancing govorestat, Applied's lead CNS-penetrant aldose reductase inhibitor targeting rare metabolic diseases including Classic Galactosemia and CMT-SORD. - Applied Therapeutics received an $8.5 million promissory note from Cycle to fund operations, as the company would otherwise be unable to continue activities for more than a limited number of days. - The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions including tender of a majority of outstanding shares.
- McKesson Corporation has secured distribution agreements for two novel oncology therapies, LYMPHIR and PHYRAGO, reinforcing its position in the specialty pharmaceutical market. - LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma developed by Citius Oncology, will be distributed nationwide through McKesson's network. - PHYRAGO, Cycle Pharmaceuticals' first oncology product launched in partnership with Handa Therapeutics, is exclusively available through Onco360 with McKesson providing distribution support. - These partnerships demonstrate McKesson's strategic focus on high-growth therapeutic areas and its role in making complex cancer treatments broadly accessible to patients across the United States.
- Cycle Pharmaceuticals has entered an exclusive U.S. commercialization agreement with Handa Therapeutics for PHYRAGO, an FDA-approved dasatinib formulation for treating Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. - PHYRAGO represents a significant advancement over existing dasatinib therapy by allowing concomitant use with proton pump inhibitors and H2 receptor antagonists without clinically significant reduction in bioavailability. - The partnership will launch PHYRAGO in September 2025 with comprehensive patient support services, marking Cycle Pharma's first oncology product and ninth commercial offering overall.
- The FDA approved nitisinone (Harliku) as the first and only treatment for alkaptonuria, a rare genetic metabolic disorder affecting 1 in 250,000 to 1 million Americans. - A 3-year randomized clinical trial of 40 patients demonstrated that nitisinone improved pain, energy levels, and physical functioning compared to untreated controls. - Alkaptonuria causes buildup of homogentisic acid leading to joint problems, ochronosis, and complications in kidneys and heart, with the medication expected to launch in July 2025. - The approval represents a significant breakthrough for patients who previously had no approved therapeutic options for this debilitating condition.
- Cycle Pharmaceuticals has launched VENXXIVA (tiopronin) Delayed-Release Tablets for treating cystinuria in the US, partnering with Torrent Pharma and Vanscoy Rare Pharmacy for distribution. - VENXXIVA is indicated for patients aged 9 and older with severe homozygous cystinuria who don't respond to high fluid intake, alkali, and diet modification alone, with tablets available in 100mg and 300mg doses. - The treatment includes access to Cycle Vita patient support services, offering financial assistance, product information, and clinical education including dietary and nutritional guidance for eligible patients.
